Program
emicizumab
Its studies are mostly in Hemophilia A, led by 2 companies.
Drug pageEmicizumab: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 123 open or running | phase 4since Nov 20, 2017 | Dec 2, 2015 | Nov 19, 2026phase 4 · NCT05181618 |
| Sanofi | 11 open or running | phase 4since Nov 17, 2023 | Nov 17, 2023 | May 28, 2028phase 4 · NCT06145373 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named emicizumabINNProposed as its International Nonproprietary Name in WHO's List 113
- Nov 17, 2023First study: phase 4 study in Hemophilia AFirst studyNCT06145373 · 20 planned · United States, Taiwan
Ahead
- May 28, 2028Primary completion: phase 4 study in Hemophilia ANCT06145373
TargetBeta
“Coagulation factor IX and X other”ChEMBL 37, by rule
Studies
The one study Sanofi leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06145373Hemophilia A · United States, Taiwan | 4 | Recruiting | May 28, 2028 | 20 |
How it is read
Names in the registry
- “Emicizumab”, 13 entries
Conditions, from the studies’ own filings
- Hemophilia A, 12 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.